News

Company   ImmuPharma PLC
TIDM         IMM
Headline    Board Changes
Released    07:01 01-May-07
Number     8285V

FOR IMMEDIATE RELEASE

London, 1 May 2007

PRELIMINARY RESULTS

for the period ended 31st December 2006

ImmuPharma plc (LSE:IMM), the specialist pharmaceutical discovery and development company is pleased to announce its preliminary results for the period ended 31st December 2006.

Key Highlights:

• Successful completion of Phase II trial of our lead compound IPP-201101, for the treatment of Lupus.

• Positive discussions held with FDA and plans for a PhaseII/III multicentre study in the US and Europe.

• Cash reserves strengthened with a further €7m funds raised.

Dimitri Dimitriou, Chief Executive Officer, said: "During our first year as a public company we have enjoyed strong share price performance and continued success in the development of our key asset, compound IPP-201101, for the treatment of Lupus. The focus for the year ahead will be on the next phase of trials for IPP-201101, and to advance our analgesic and antibiotic compounds and to engage in continuing out-licensing dialogue with large biotech and pharmaceutical companies worldwide."

ImmuPharma PLC

Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080
Richard Warr, Chairman +44 20 7152 4080

Buchanan Communications + 44 20 7466 5000

Lisa Baderoon
Rebecca Skye-Dietrich

Click here to view the full document:

ImmuPharma Preliminary Results 2006.pdf


Home About ImmuPharma Lead compounds Discovery pipeline Management team News For Investors Contact us	News Company ImmuPharma PLC TIDM IMM Headline Board Changes Released 07:01 01-May-07 Number 8285V FOR IMMEDIATE RELEASE London, 1 May 2007 PRELIMINARY RESULTS for the period ended 31st December 2006 ImmuPharma plc (LSE:IMM), the specialist pharmaceutical discovery and development company is pleased to announce its preliminary results for the period ended 31st December 2006. Key Highlights: • Successful completion of Phase II trial of our lead compound IPP-201101, for the treatment of Lupus. • Positive discussions held with FDA and plans for a PhaseII/III multicentre study in the US and Europe. • Cash reserves strengthened with a further €7m funds raised. Dimitri Dimitriou, Chief Executive Officer, said: "During our first year as a public company we have enjoyed strong share price performance and continued success in the development of our key asset, compound IPP-201101, for the treatment of Lupus. The focus for the year ahead will be on the next phase of trials for IPP-201101, and to advance our analgesic and antibiotic compounds and to engage in continuing out-licensing dialogue with large biotech and pharmaceutical companies worldwide." ImmuPharma PLC Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080 Richard Warr, Chairman +44 20 7152 4080 Buchanan Communications + 44 20 7466 5000 Lisa Baderoon Rebecca Skye-Dietrich Click here to view the full document: ImmuPharma Preliminary Results 2006.pdf